SCHEMBL18952149

SCHEMBL18952149

Fc1ccc(C(Cc2ccccc2)NC2CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.43
CHRM1 P11229 1/20 0.43
SLC6A2 P23975 1/20 0.43
CYP19A1 P11511 1/20 0.42
DRD2 P14416 3/20 0.41
DRD3 P35462 3/20 0.41
DRD4 P21917 2/20 0.41
SLC6A3 Q01959 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
CNR2 P34972 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28426623 0.94 MEN1 (0.41) SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4
SCHEMBL18952114 0.84 MMP2 (0.40) ALDH1A1HTTCYP1A2CYP3A4CYP2D6
SCHEMBL28896351 0.78 SLC18A3 (0.40) SLC6A4ALDH1A1HTTCYP1A2CYP3A4
SCHEMBL28428823 0.75 SIGMAR1 (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL8400412 0.71 HTR1D (0.43) SLC6A4CHRM1SLC6A2
SCHEMBL15627637 0.71 ESR1 (0.52) SLC6A4SLC6A2CYP19A1SLC6A3ALDH1A1
SCHEMBL28496737 0.71 KDM1A (0.44) SLC6A4SLC6A2SLC6A3ALDH1A1HTT
SCHEMBL29022785 0.70 SLC6A4 (0.66) SLC6A4CHRM1SLC6A2
SCHEMBL13144345 0.70 ALDH1A1 (0.49) ALDH1A1HTTCNR2
SCHEMBL16226357 0.70 SLC6A3 (0.66) SLC6A4SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017097865-A9 COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR ISTITUTO EUROPEO DI ONCOLOGIA (IT) 2017-08-31 WO disclosed
WO-2017097865-A1 COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR ISTITUTO EUROPEO DI ONCOLOGIA (IT) 2017-06-15 WO disclosed